globenewswire

LONDON, UK and ATLANTA, Dec. 11, 2023 (GLOBE NEWSWIRE) — Descartes Systems Group (Nasdaq: DSGX) (TSX: DSG), the global leader in uniting logistics-intensive businesses in commerce, announced that U.K.-based ecommerce …

Veteran MedTech leader and hospital group CEO joins CMR Surgical as global Chief Commercial Officer Massimiliano Colella joins as global Chief Commercial Officer leading CMR Surgical’s commercial and marketing operations …

MILPITAS, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) — Lumissil Microsystems, a division of Integrated Silicon Solution, Inc. (ISSI), announces the release of the IS32LT3131 its latest LED driver IC for …

Glycotope and Evotec enter licensing agreement to combine Glycotope antibodies and Evotec’s immune cell engager platform Berlin, Germany, 11 December 2023 – Glycotope GmbH (Glycotope) has signed an agreement with Evotec …

Press release Canal de Isabel II awards Eviden and Ayesa the innovative Yara project to transform its commercial and customer management system Madrid, Spain and Paris, France – December 11 …

Additional data from the Phase 2 CAPTIVATE study, show 82 percent of patients with previously untreated chronic lymphocytic leukaemia (CLL) treated with fixed-duration ibrutinib plus venetoclax did not need next-line …

TAINAN, Taiwan, Dec. 11, 2023 (GLOBE NEWSWIRE) — Himax Technologies, Inc. (Nasdaq: HIMX) (“Himax” or “Company”), a leading supplier and fabless manufacturer of display drivers and other semiconductor products, today …

Significant overall Response Rate (ORR) achieved in both HR-MDS (5/5) and HMA-failed MDS (5/5) patients The vast majority of responses are deep and durable with 7/10 MDS patients achieving CR/mCR …

Company announcement no. 28 / 2023Schindellegi, Switzerland – 11 December 2023 Trifork Holding AG – Weekly report on share buyback On 2 November 2023, Trifork initiated a share buyback program …

Clinical activity observed in 50% of evaluable patients with relapsed/refractory acute myeloid leukemia (r/r AML) or high-risk myelodysplastic syndromes (HR-MDS) treated with RVU120 monotherapy, including a complete response. Treatment continues …